GB0216416D0 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
GB0216416D0
GB0216416D0 GBGB0216416.8A GB0216416A GB0216416D0 GB 0216416 D0 GB0216416 D0 GB 0216416D0 GB 0216416 A GB0216416 A GB 0216416A GB 0216416 D0 GB0216416 D0 GB 0216416D0
Authority
GB
United Kingdom
Prior art keywords
crystals
size
correlated
plasma
stable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0216416.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9940486&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB0216416(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB0216416.8A priority Critical patent/GB0216416D0/en
Publication of GB0216416D0 publication Critical patent/GB0216416D0/en
Priority to ES03756455T priority patent/ES2279153T3/es
Priority to DK03756455T priority patent/DK1523335T3/da
Priority to AU2003281154A priority patent/AU2003281154B2/en
Priority to EP03756455A priority patent/EP1523335B1/en
Priority to AT03756455T priority patent/ATE348635T1/de
Priority to SI200330610T priority patent/SI1523335T1/sl
Priority to HK05108084.5A priority patent/HK1076029B/en
Priority to PT03756455T priority patent/PT1523335E/pt
Priority to US10/521,064 priority patent/US20050250813A1/en
Priority to PCT/EP2003/007619 priority patent/WO2004006886A2/en
Priority to NZ537598A priority patent/NZ537598A/en
Priority to DE60310564T priority patent/DE60310564T2/de
Priority to JP2004520629A priority patent/JP5392961B2/ja
Priority to CA2492467A priority patent/CA2492467C/en
Priority to ZA200410323A priority patent/ZA200410323B/en
Priority to CY20061101867T priority patent/CY1106305T1/el
Priority to US12/254,925 priority patent/US20090099232A1/en
Priority to JP2010236087A priority patent/JP5670698B2/ja
Priority to US13/106,417 priority patent/US8293765B2/en
Priority to US13/401,310 priority patent/US8227488B2/en
Priority to US13/618,753 priority patent/US8614232B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GBGB0216416.8A 2002-07-15 2002-07-15 Organic compounds Ceased GB0216416D0 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
GBGB0216416.8A GB0216416D0 (en) 2002-07-15 2002-07-15 Organic compounds
JP2004520629A JP5392961B2 (ja) 2002-07-15 2003-07-14 イロペリドンの結晶を含有する注射用デポ製剤
CA2492467A CA2492467C (en) 2002-07-15 2003-07-14 Injectable depot formulation comprising crystals of iloperidone
US10/521,064 US20050250813A1 (en) 2002-07-15 2003-07-14 Injectable depot formulation comprising crystals of iloperidone
DE60310564T DE60310564T2 (de) 2002-07-15 2003-07-14 Injizierbare depotformulierung enthaltend iloperidonkrystalle
AU2003281154A AU2003281154B2 (en) 2002-07-15 2003-07-14 Injectable depot formulation comprising cyrstals of iloperidone
EP03756455A EP1523335B1 (en) 2002-07-15 2003-07-14 Injectable depot formulation comprising crystals of iloperidone
AT03756455T ATE348635T1 (de) 2002-07-15 2003-07-14 Injizierbare depotformulierung enthaltend iloperidonkrystalle
SI200330610T SI1523335T1 (sl) 2002-07-15 2003-07-14 Depojska formulacija za injiciranje, ki vsebuje kristale iloperidona
HK05108084.5A HK1076029B (en) 2002-07-15 2003-07-14 Injectable depot formulation comprising crystals of iloperidone
PT03756455T PT1523335E (pt) 2002-07-15 2003-07-14 Formulação injectável para um depósito compreendendo cristais de iloperidona
ES03756455T ES2279153T3 (es) 2002-07-15 2003-07-14 Formulacion de depositio inyectable formada por cristales de iloperidona.
PCT/EP2003/007619 WO2004006886A2 (en) 2002-07-15 2003-07-14 Injectable depot formulation comprising crystals of iloperidone
NZ537598A NZ537598A (en) 2002-07-15 2003-07-14 Injectable depot formulation comprising crystals of iloperidone
DK03756455T DK1523335T3 (da) 2002-07-15 2003-07-14 Injicerbar depotformulering omfattende iloperidonkrystaller
ZA200410323A ZA200410323B (en) 2002-07-15 2004-12-22 Injectable depot formulation comprising crystals of iloperidone
CY20061101867T CY1106305T1 (el) 2002-07-15 2006-12-29 Ενεσιμη συνθεση αποθεματος πepιλαμβανουσα κρυσταλλους ιλοπepιδονης
US12/254,925 US20090099232A1 (en) 2002-07-15 2008-10-21 Injectable depot formulation comprising crystals of iloperidone
JP2010236087A JP5670698B2 (ja) 2002-07-15 2010-10-21 イロペリドンの結晶を含有する注射用デポ製剤
US13/106,417 US8293765B2 (en) 2002-07-15 2011-05-12 Injectable depot formulation comprising crystals of iloperidone
US13/401,310 US8227488B2 (en) 2002-07-15 2012-02-21 Injectable depot formulation comprising crystals of iloperidone
US13/618,753 US8614232B2 (en) 2002-07-15 2012-09-14 Injectable depot formulation comprising crystals of iloperidone

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0216416.8A GB0216416D0 (en) 2002-07-15 2002-07-15 Organic compounds

Publications (1)

Publication Number Publication Date
GB0216416D0 true GB0216416D0 (en) 2002-08-21

Family

ID=9940486

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0216416.8A Ceased GB0216416D0 (en) 2002-07-15 2002-07-15 Organic compounds

Country Status (15)

Country Link
US (5) US20050250813A1 (https=)
EP (1) EP1523335B1 (https=)
JP (2) JP5392961B2 (https=)
AT (1) ATE348635T1 (https=)
AU (1) AU2003281154B2 (https=)
CA (1) CA2492467C (https=)
CY (1) CY1106305T1 (https=)
DE (1) DE60310564T2 (https=)
DK (1) DK1523335T3 (https=)
ES (1) ES2279153T3 (https=)
GB (1) GB0216416D0 (https=)
NZ (1) NZ537598A (https=)
PT (1) PT1523335E (https=)
WO (1) WO2004006886A2 (https=)
ZA (1) ZA200410323B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8227488B2 (en) 2002-07-15 2012-07-24 Novartis Ag Injectable depot formulation comprising crystals of iloperidone

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2436439T3 (es) 2001-10-30 2014-01-02 Novartis Ag Formulaciones de medicamento de liberación lenta de iloperidona con un polímero
ATE411797T2 (de) 2003-10-23 2008-11-15 Otsuka Pharma Co Ltd Sterile injizierbare aripiprazol-formulierung mit kontrollierter freisetzung und verfahren
EP1799865B1 (en) 2004-09-30 2012-06-06 Vanda Pharmaceuticals Inc. Methods for the administration of iloperidone
US20100063093A1 (en) 2007-03-28 2010-03-11 Curt Wolfgang Methods for the administration of iloperidone
US20090306137A1 (en) 2006-05-22 2009-12-10 Wolfgang Curt D Treatment for depressive disorders
US8198305B2 (en) 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
MY152789A (en) 2007-07-31 2014-11-28 Otsuka Pharma Co Ltd Methods for producing aripiprazole suspension and freeze-dried formulation
EP2198048A2 (en) 2007-09-10 2010-06-23 Vanda Pharmaceuticals Inc. Prediction of qt prolongation based on snp genotype
BRPI0820993A2 (pt) 2007-12-13 2017-05-09 Vanda Pharmaceuticals Inc método e composição para tratar uma condição mediada por alfa adrenoceptor
SI2222300T1 (sl) 2007-12-13 2014-11-28 Vanda Pharmaceuticals Inc. Postopek in sestavek za zdravljenje stanja, posredovanega z receptorjem serotonina
WO2010031497A1 (en) * 2008-09-19 2010-03-25 Miklos Vertessy New process for the preparation of iloperidone
CN101822673B (zh) * 2009-03-04 2013-09-18 北京德众万全药物技术开发有限公司 一种含有伊潘立酮的固体药物组合物
US20120136050A1 (en) 2009-07-16 2012-05-31 Vanda Pharmaceuticals Inc. Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
EP2479176B1 (en) * 2009-09-19 2014-09-17 Zhejiang Huahai Pharmaceutical Co., Ltd. Method for preparation of iloperidone and crystallization method thereof
CN102030744B (zh) * 2009-09-30 2013-04-17 天津药物研究院 伊潘立酮晶体、其制备方法及药物组合物
WO2011055188A1 (en) * 2009-11-05 2011-05-12 Orchid Chemicals And Pharmaceuticals Limited An improved process for the preparation of iloperidone
MX2012007365A (es) * 2009-12-23 2012-08-15 Lupin Ltd Composiciones farmaceuticas de liberacion lenta de iloperidona.
CN102108081A (zh) * 2009-12-25 2011-06-29 重庆医药工业研究院有限责任公司 伊潘立酮的新晶型及其制备方法
LT2523669T (lt) 2010-01-11 2017-04-25 Inotek Pharmaceuticals Corporation Akispūdžio mažinimo būdas, derinys ir rinkinys
PH12012501906A1 (en) 2010-03-26 2013-01-14 Inotek Pharmaceuticals Corp Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof
CN101822674B (zh) * 2010-05-27 2015-03-11 北京德众万全医药科技有限公司 一种伊潘立酮药物组合物及其制备方法
JP5893616B2 (ja) * 2010-10-18 2016-03-23 大日本住友製薬株式会社 注射用徐放性製剤
WO2012063269A2 (en) 2010-11-12 2012-05-18 Cadila Healthcare Limited Process for preparing iloperidone
WO2012090138A1 (en) 2010-12-27 2012-07-05 Ranbaxy Laboratories Limited Processes for the preparation of iloperidone
CN102680636A (zh) * 2011-03-11 2012-09-19 天津药物研究院 一种伊潘立酮原料药及其中间体的质量控制方法
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
WO2013112951A2 (en) 2012-01-26 2013-08-01 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
PT2807178T (pt) 2012-01-26 2017-08-08 Inotek Pharmaceuticals Corp Polimorfos anidros de nitrato de (2r,3s,4r,5r)-5-(6-(ciclopentilamino)-9h-purin-9-il)-3,4-dihidroxitetrahidrofuran-2-il)}metilo e seus processos de preparação
CN102659771B (zh) * 2012-04-18 2013-11-27 吉林三善恩科技开发有限公司 一种伊潘立酮药物共晶及其制备方法
CN102633786B (zh) * 2012-04-18 2013-11-27 吉林三善恩科技开发有限公司 一种伊潘立酮药物共晶及其制备方法
BR112014028446A2 (pt) 2012-05-18 2017-10-24 Vanda Pharmaceuticals Inc composto isolado, composição farmacêutica, método de tratamento ou prevenção de pelo menos um de doenças, distúrbios ou condições seguintes, e, método de tratamento ou prevenção de um distúrbio de ritmo circadiano ou distúrbio com um componente circadiano em um indivíduo
KR102148990B1 (ko) 2012-12-18 2020-08-27 반다 파마슈티칼즈, 인코퍼레이티드. 일주기 리듬 장애의 치료
NZ630759A (en) 2013-03-15 2017-07-28 Inotek Pharmaceuticals Corp Ophthalmic formulations comprising an a1 agonist
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
CN103599074A (zh) * 2013-11-26 2014-02-26 重庆医药工业研究院有限责任公司 一种伊潘立酮缓释微球及其制备方法
WO2016134049A1 (en) 2015-02-17 2016-08-25 Vanda Pharmaceuticals Inc. Iloperidone for the treatment of schizophrenia
US11071728B2 (en) 2015-12-11 2021-07-27 Vanda Pharmaceuticals Inc. Treatment of schizophrenia
CN106831741B (zh) * 2016-12-28 2019-08-23 北京医药集团有限责任公司 一种伊潘立酮超细粉体的制备方法
US10935106B2 (en) * 2018-06-14 2021-03-02 Serapid, Inc. Block chain with monolithic links
CN113164382A (zh) * 2018-12-04 2021-07-23 万达制药公司 伊潘立酮的贮库施用
US20200171018A1 (en) * 2018-12-04 2020-06-04 Vanda Pharmaceuticals Inc. Depot administration of iloperidone
US11607408B2 (en) 2019-10-15 2023-03-21 Vanda Pharmaceuticals Inc. Method of treatment of schizophrenia
WO2024137439A1 (en) 2022-12-19 2024-06-27 Vanda Pharmaceuticals Inc. Dosage regime of iloperidone for treating bipolar i disorder and schizophrenia

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB216416A (en) 1923-09-06 1924-05-29 James Baker And Sons Ltd Improvements in boots and shoes
IT1093097B (it) * 1976-10-28 1985-07-19 Hoechst France Acidi n-carbetossi(alfa-amminofenilacetici)otticamente attivi relativo procedimento di produzione e loro impiego per la produzione di acidi alfa-ammino-fenilacetici otticamente attivi corrispondenti
CH656884A5 (de) 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
DE3345355A1 (de) * 1983-12-15 1985-06-27 Hoechst Ag, 6230 Frankfurt Verfahren zur racematspaltung bicyclischer imino-(alpha)-carbonsaeureester
DE3511587A1 (de) 1985-03-27 1986-10-02 Schering AG, Berlin und Bergkamen, 1000 Berlin Glykoester des estradiols und estriols
US4886370A (en) 1987-08-25 1989-12-12 Nkk Corporation Method for detecting a state of substance existing in pipe
US5364866A (en) * 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
US5776963A (en) * 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
ES2076253T3 (es) * 1989-05-19 1995-11-01 Hoechst Roussel Pharma N-(ariloxialquil)-heteroarilpiperidinas y -heteroarilpiperazinas, un procedimiento para su preparacion y su uso como medicamentos.
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
WO1991018927A1 (en) * 1990-06-04 1991-12-12 Schering Corporation Method for preparing interferon alpha-2 crystals
CA2095499A1 (en) * 1992-05-08 1993-11-09 Petrus J. M. Van Den Oetelaar Depot preparation
CA2148823C (en) 1992-11-17 1999-03-09 Welfide Corporation Sustained release microsphere preparation containing antipsychotic drug and production process thereof
CN1074923C (zh) 1993-11-19 2001-11-21 詹森药业有限公司 微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类
US5902882A (en) * 1996-04-17 1999-05-11 Hoffmann-La Roche Inc. Assymetric synthesis of azepines
TW487572B (en) * 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
PL337027A1 (en) * 1997-05-26 2000-07-31 Akzo Nobel Nv Salts of aromatic sulphonic acids
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US6541606B2 (en) * 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
DE19816070A1 (de) 1998-04-09 1999-10-14 Aventis Res & Tech Gmbh & Co Retardtablette hergestellt aus linearen wasserunlöslichen Polysacchariden
PL348107A1 (en) 1998-10-16 2002-05-06 Janssen Pharmaceutica Nv Therapy for improving cognition
US6509310B1 (en) 2000-06-01 2003-01-21 Huish Detergents, Inc. Compositions containing α-sulfofatty acid esters and method of making the same
AU2001263775A1 (en) 2000-06-02 2001-12-11 Novo-Nordisk A/S Glucose dependent release of insulin from glucose sensing insulin derivatives
DK1425272T3 (da) * 2001-08-31 2011-11-21 Novartis Ag Optiske isomerer af en iloperidon-metabolit
ES2436439T3 (es) * 2001-10-30 2014-01-02 Novartis Ag Formulaciones de medicamento de liberación lenta de iloperidona con un polímero
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8227488B2 (en) 2002-07-15 2012-07-24 Novartis Ag Injectable depot formulation comprising crystals of iloperidone
US8293765B2 (en) 2002-07-15 2012-10-23 Novartis Ag Injectable depot formulation comprising crystals of iloperidone
US8614232B2 (en) 2002-07-15 2013-12-24 Novartis Ag Injectable depot formulation comprising crystals of iloperidone

Also Published As

Publication number Publication date
DK1523335T3 (da) 2007-01-29
WO2004006886A3 (en) 2004-02-19
US20120156264A1 (en) 2012-06-21
ES2279153T3 (es) 2007-08-16
ATE348635T1 (de) 2007-01-15
HK1076029A1 (en) 2006-01-06
JP2005533093A (ja) 2005-11-04
PT1523335E (pt) 2007-02-28
CA2492467A1 (en) 2004-01-22
US20110212141A1 (en) 2011-09-01
CY1106305T1 (el) 2011-10-12
EP1523335A2 (en) 2005-04-20
JP2011016849A (ja) 2011-01-27
WO2004006886A2 (en) 2004-01-22
NZ537598A (en) 2006-07-28
JP5392961B2 (ja) 2014-01-22
EP1523335B1 (en) 2006-12-20
JP5670698B2 (ja) 2015-02-18
AU2003281154A1 (en) 2004-02-02
ZA200410323B (en) 2006-06-28
US8614232B2 (en) 2013-12-24
US20090099232A1 (en) 2009-04-16
US8293765B2 (en) 2012-10-23
DE60310564T2 (de) 2007-10-04
DE60310564D1 (de) 2007-02-01
US8227488B2 (en) 2012-07-24
CA2492467C (en) 2010-03-16
AU2003281154B2 (en) 2006-10-12
US20130012542A1 (en) 2013-01-10
US20050250813A1 (en) 2005-11-10

Similar Documents

Publication Publication Date Title
GB0216416D0 (en) Organic compounds
ES2500068T3 (es) Inhibidores heterocíclicos de MEK y métodos de uso de los mismos
CO6311078A2 (es) Compuestos heterociclicos que contienen dos o más heteroanillos, que contienen átomos de nitrogeno como únicos heteroátomos en el anillo, en donde al menos un anillo es de 6 miembros con un átomo de nitrógeno, que contienen tres ó más heteroátomos, c
AR004701A1 (es) 2-azetidinonas substituidas con azucares utiles como agentes hipocolesterolemicos, composicion farmaceutica, proceso para la preparacion dedicha composicion, uso de dichos compuestos para fabricar medicamentos y un equipo.
TW200626558A (en) Indazolone derivatives
EA200601299A1 (ru) Яркие и быстродействующие нейтронные сцинтилляторы
IL164509A0 (en) Furyl compounds
MX2007013065A (es) Derivados de dihidrobenzofurano y usos de los mismos.
AR073689A1 (es) Derivados de azaindazol, antagonistas de receptores ccr1, composiciones farmaceuticas que los contienen, metodo de preparacion de los mismos y de intermediarios, y uso para tratar enfermedades autoinmunes ,diabetes y alzheimer, entre otras.
BRPI0412659A (pt) isÈmero c de cci-779, seu processo de preparação, composição farmacêutica compreendendo o mesmo e pacote farmacêutico contendo o referido composto
TNSN08022A1 (en) Novel macrocyclic inhibitors of hepatitis c virus replication
DE60328010D1 (de) Heterocyclische verbindungen
MXPA06000921A (es) Derivados de benzamidazoles como inhibidores de mek.
AR034120A1 (es) Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico
MY144209A (en) Pyridazine derivatives as 11beta-hydroxysteroid dehydrogenase type 1 inhibitors
AR010321A1 (es) Granulos utiles para aplicaciones de oxidacion cuando se disuelven en presencia de una fuente activa de oxigeno, y composicion blanqueadora quecomprende a dichos granulos
NZ718514A (en) Compounds, compositions and methods useful for cholesterol mobilisation
BRPI0600194A (pt) composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
JP2004532344A5 (https=)
BRPI0411265A (pt) métodos para a preparação de composições de polpa de fruta estabilizada e de purê estável
DE502005008631D1 (de) Dermatologischen zubereitungen
ID30350A (id) Komposisi polikarbonat yang bermanfaat dalam penggunaan alat penyimpan optik
GB0012383D0 (en) Organic compounds
AU2006290679A8 (en) High light yield fast scintillator

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)